Source: Healio News
Using circulating tumor DNA to predict relapse after autologous stem cell transplantation in patients with multiple myeloma showed feasibility in a study presented at the virtual ASCO Annual Meeting.
Minimal residual disease (MRD) detected by bone marrow-based assay is an important prognostic marker of relapse in multiple myeloma, according to Binod Dhakal, MD, associate professor of medicine in the division of hematology at the Medical College of Wisconsin.
“MRD in multiple myeloma is monitored by a first-pull marrow aspirate, but are limited by the spatial heterogeneity of marrow,